Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Osteoporosis

Romosozumab to rebuild the foundations of bone strength

Nature Reviews Rheumatology volume 14, page 128 (2018)Cite this article

Subjects

Biologic agents targeting key proteins involved in bone homeostasis are revolutionizing the management of osteoporosis. New clinical data support the use of these novel therapies to rapidly increase bone mass and decrease the risk of fractures.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Differential effects of bone-forming agents on bone surfaces.

References

  1. Saag, K. G. et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N. Engl. J. Med. 377, 1417–1427 (2017).

    Article  CAS  Google Scholar 

  2. Ke, H. Z., Richards, W. G., Li, X. & Ominsky, M. S. Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. Endocr. Rev. 33, 747–783 (2012).

    Article  CAS  Google Scholar 

  3. Baron, R., Ferrari, S. & Russell, R. G. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone 48, 677–692 (2011).

    Article  CAS  Google Scholar 

  4. Miller, P. D. et al. Effect of abaloparatide versus placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA 316, 722–733 (2016).

    Article  CAS  Google Scholar 

  5. Ominsky, M. S. et al. Sustained modeling-based bone formation during adulthood in cynomolgus monkeys may contribute to continuous BMD gains with denosumab. J. Bone Miner. Res. 30, 1280–1289 (2015).

    Article  CAS  Google Scholar 

  6. McClung, M. R. et al. Romosozumab in postmenopausal women with low bone mineral density. N. Engl. J. Med. 370, 412–420 (2014).

    Article  CAS  Google Scholar 

  7. Langdahl, B. L. et al. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet 390, 1585–1594 (2017).

    Article  CAS  Google Scholar 

  8. Cosman, F., Crittenden, D. B. & Grauer, A. Romosozumab treatment in postmenopausal osteoporosis. N. Engl. J. Med. 376, 396–397 (2017).

    PubMed  Google Scholar 

  9. Bone, H. G. et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 5, 513–523 (2017).

    Article  CAS  Google Scholar 

  10. Kranenburg, G. et al. Bisphosphonates for cardiovascular risk reduction: a systematic review and meta-analysis. Atherosclerosis 252, 106–115 (2016).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service and Laboratory of Bone Diseases, Geneva University Hospital, Geneva, 1205, Switzerland

    Serge L. Ferrari

Authors
  1. Serge L. Ferrari
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Serge L. Ferrari.

Ethics declarations

Competing interests

The author declares that he has received research funding and consultancy fees from Amgen, MSD and UCB.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ferrari, S. Romosozumab to rebuild the foundations of bone strength. Nat Rev Rheumatol 14, 128 (2018). https://doi.org/10.1038/nrrheum.2018.5

Download citation

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrrheum.2018.5

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing